National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

When Jennifer Woyach, MD, started as a resident and fellow two decades ago, patients with chronic lymphocytic leukemia (CLL) ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

single-arm trial assessed the combination of the therapy and Brukinsa (zanubrutinib), a Bruton tyrosine kinase (BTK) inhibitor, and reported an overall response rate of 67%. The study enrolled ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...